Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The Ultrasound Monitoring to the Venous Thromboembolism Associated with Peripherally Inserted Central Catheters in Chemotherapy Patients: A Prospective Cohort Study

View through CrossRef
Abstract Objective: To investigate the incidence of peripherally inserted central catheter–related deep venous thrombosis (PRDVT) and their associated risk factors of PRDVT in the oncological patients who received peripherally inserted central catheters. Methods: This is a prospective and interventional cohort study; enrolled cancer patients had ultrasound-guided peripherally inserted central catheters and followed up by an intensive ultrasound monitoring protocol for 24 weeks. Vascular color Doppler ultrasound was applicated to the prospective evaluation of thrombus every 2 weeks for each patient. Results: Of all 406 patients (37,490 catheter days), 30.05% of patients (122/406) developed peripherally inserted central catheter–related deep vein thrombosis, with an incidence of 3.25 per 1000 catheter days. Only 1.23% (5/406) peripherally inserted central catheters were removed because of central line associated blood stream infection or accident. The incidence of asymptomatic PRDVT and symptomatic PRDVT were 26.85% (109/406) and 3.2% (13/406) respectively. Conclusion: The incidence of PRDVT in our hospital was considerable to the published data. Catheter in right upper extremity, tip at subclavian or T 2-4, more than 1 attempt for peripherally inserted central catheter insertion, and radiotherapy were independent predictors of PRDVT in cancer patients. Proactive ultrasound monitoring protocol from insertion to follow-up visits to investigate the incidence of PRDVT in oncological patients should be a routine examination.
Title: The Ultrasound Monitoring to the Venous Thromboembolism Associated with Peripherally Inserted Central Catheters in Chemotherapy Patients: A Prospective Cohort Study
Description:
Abstract Objective: To investigate the incidence of peripherally inserted central catheter–related deep venous thrombosis (PRDVT) and their associated risk factors of PRDVT in the oncological patients who received peripherally inserted central catheters.
Methods: This is a prospective and interventional cohort study; enrolled cancer patients had ultrasound-guided peripherally inserted central catheters and followed up by an intensive ultrasound monitoring protocol for 24 weeks.
Vascular color Doppler ultrasound was applicated to the prospective evaluation of thrombus every 2 weeks for each patient.
Results: Of all 406 patients (37,490 catheter days), 30.
05% of patients (122/406) developed peripherally inserted central catheter–related deep vein thrombosis, with an incidence of 3.
25 per 1000 catheter days.
Only 1.
23% (5/406) peripherally inserted central catheters were removed because of central line associated blood stream infection or accident.
The incidence of asymptomatic PRDVT and symptomatic PRDVT were 26.
85% (109/406) and 3.
2% (13/406) respectively.
Conclusion: The incidence of PRDVT in our hospital was considerable to the published data.
Catheter in right upper extremity, tip at subclavian or T 2-4, more than 1 attempt for peripherally inserted central catheter insertion, and radiotherapy were independent predictors of PRDVT in cancer patients.
Proactive ultrasound monitoring protocol from insertion to follow-up visits to investigate the incidence of PRDVT in oncological patients should be a routine examination.

Related Results

Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract Introduction  Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Direct costs for treatment of venous thromboembolism complication 90-day after surgery
Direct costs for treatment of venous thromboembolism complication 90-day after surgery
Study object: Describe the direct treatment costs due to venous thromboembolism complications 90 days after surgery by using national health insurance reimbursement database. Patie...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

Back to Top